Seattle Genetics Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Seattle Genetics Reports Second Quarter 2018 Financial Results
July 27, 2018 12:22 PM EDT
Needham & Company raised its price target on Seattle Genetics (NASDAQ: SGEN) to $79.00 (from $74.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Seattle handily beat Street consensus with 2Q:18 ADCETRIS sales of $122M, higher than our $109M and similar Street... More
July 27, 2018 11:29 AM EDT
Cowen raised its price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $54.00) while maintaining a Outperform rating
Analyst Boris Peaker noted strength was driven by strong adoption in the frontline HL by community docs, although he said the recent stock run-up factors in this stronger uptake.
...
More
July 27, 2018 8:05 AM EDT
SunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $81.00 (from $80.00) while maintaining a Buy rating.
Analyst Yatin Suneja commented, "Adcetris surprised with another stronger than expected 2Q18 sales (+14%/$14.8MM vs. consensus), on robust uptake in frontline (1L) cHL.... More
July 26, 2018 4:05 PM EDT
Seattle Genetics (NASDAQ: SGEN) reported Q2 EPS of $0.47, versus ($0.39) reported last year. Revenue for the quarter came in at $170.17 million versus the consensus estimate of $141.07 million.
Our ADCETRIS sales growth in the first full quarter following FDA approval in frontline Stage III or IV classical Hodgkin lymphoma demonstrates a strong reception from the oncology... More
